NEWBORN SCREEN - 17-HYDROXYPROGESTERONE (CAH SCREEN)
MRP - ₹ 280
What is a NEWBORN SCREEN - 17-HYDROXYPROGESTERONE (CAH SCREEN)?
The Newborn Screen – 17-Hydroxyprogesterone (CAH Screen) is a specialized test performed shortly after birth to detect elevated levels of 17-hydroxyprogesterone, a marker for congenital adrenal hyperplasia (CAH). CAH is a genetic disorder affecting adrenal gland function, leading to hormone imbalances that can cause serious health complications if untreated. This screening is done to enable early diagnosis and timely intervention, ensuring proper management, preventing life-threatening crises, and supporting healthy growth and development in newborns.
Additional Information
| Also known as/ Other names: | Congenital Adrenal Hyperplasia (CAH), Newborn Screen, Newborn 17-OHP Screening, CAH Screen – 17-Hydroxyprogesterone, Dried Blood Spot 17-OHP (CAH), Newborn CAH (17-OHP) Screen |
| Parameters: | 1 |
| Recommended for: | M/F/Others |
| Sample Type: | 3 heel prick blood spots on filter paper from LAB |
| Patient Preparation: | Sample must be accompanied by clinical details and drug history |
| Reports: | 2 Days |
FAQs
It helps identify CAH early, preventing life-threatening salt-wasting crises and enabling timely treatment to support healthy growth and development in newborns.
All newborns are routinely screened, as CAH can occur without family history and early detection is critical for survival.
It detects congenital adrenal hyperplasia, a genetic disorder that disrupts cortisol and aldosterone production.
It suggests CAH, but confirmatory genetic or hormonal tests are required for a definitive diagnosis.
It indicates risk but cannot precisely predict severity; further testing determines the specific type and seriousness of CAH.
Yes, though results may need careful interpretation, as prematurity can affect hormone levels.
No, results are based on genetic and hormonal factors, unaffected by lifestyle.
